Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy

Area of Science:

• Immunology
• Oncology
• Genomics

Background:

• CD4+ T-cell immunity is crucial for effective antitumor responses, supporting CD8+ T-cell activity against cancer.
• Identifying specific CD4+ T-cell subsets involved in antitumor immunity is essential for developing targeted immunotherapies.

Purpose of the Study:

• To identify novel CD4+ T-cell clusters associated with antitumor immunity and response to programmed death-ligand 1 (PD-1) blockade therapy.
• To investigate the potential of these CD4+ T-cell clusters as predictive biomarkers for immunotherapy efficacy.

Main Methods:

• Single-cell RNA-sequencing was employed to analyze naïve-effector states, T-helper (Th) polarization, and T-cell receptor clonotypes.
• Unsupervised clustering analysis was used to identify distinct CD4+ T-cell subpopulations and metaclusters.

Main Results:

• A novel CD4+ T-cell metacluster within the CD62Llow subpopulation was identified, characterized by specific chemokine receptor (CXCR3, CCR4, CCR6) and transcription factor (IL7R, TCF7) expression.
• The frequency of this metacluster in peripheral blood correlated significantly with progression-free and overall survival in lung cancer patients undergoing PD-1 blockade therapy.
• Peripheral CD4+ T-cell metacluster presence associated with CD4+ T-cell tumor infiltration, while peripheral Th1 cells correlated with CD8+ T-cell infiltration.

Conclusions:

• The identified CD62Llow CCR4-CCR6+ CD4+ T-cell metacluster serves as a potential predictive biomarker for immunotherapy response.
• This finding supports the use of peripheral blood analysis to assess immune status and predict sensitivity to PD-1 blockade.
• The discovery paves the way for personalized immunotherapy strategies in cancer treatment.